The abstract is read at the publisher; the summary is JClub's.
Faricimab treat-and-extend in diabetic macular edema maintained visual and anatomic gains over RHONE-X, with adjusted BCVA improvements up to +11.4 letters and CST reductions near -205 µm.
- Why it matters: Long-term safety and durability are needed for DME patients beyond initial trials, especially under extended dosing schedules that reduce treatment burden.
- What they did: In RHONE-X, 1474 of 1622 YOSEMITE/RHINE completers received faricimab T&E up to 16-week intervals, with monthly visits during an initial 4-month masked period and AE monitoring as the primary endpoint.
- The result: Ocular and nonocular AEs leading to discontinuation were 1.5% and intraocular inflammation was 1.3%, while >90% achieved DME absence and ~80% reached ≥Q12W by trial completion.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.